The American journal of emergency medicine · 2026
Challenging the 4-h premedication regimen for iodinated contrast allergy: A multicenter retrospective study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shah Chirag N, DiGaetano Michael, Aboloff Jessica, Estrella Yonathan, Levin Daniel, Meaden Christopher, Maye Jessica, Harris Colin, Malcampo Penafrancia, Wickstrom Elena, Neyman Gregory, Bramwit Mark, Heinert Sara, McCoy Jonathan V, Peng Paul
Аннотация
STUDY OBJECTIVE: The American College of Radiology (ACR) recommends an Accelerated 4-h intravenous (IV) premedication regimen (an antihistamine and a corticosteroid) for Emergency Department (ED) patients with documented iodinated contrast allergy who require contrast-enhanced computed tomography (CT). To test the validity of the ACR recommendation, we evaluated the association between the occurrence of any contrast reaction (mild, moderate, or severe) and the timing of contrast administration (≤ 4 vs > 4 h) among premedicated patients.
METHODS: Retrospective cohort chart analysis across five EDs (January 2022-December 2024) of patients ≥21 years old with a documented iodinated contrast allergy, who received premedication before contrast-enhanced CT imaging. The primary outcome was the proportion of any contrast reaction (mild, moderate, or severe), as defined by the 2025 ACR Contrast Media Manual. Chi-square analysis was used to compare the reaction events in the 4-h premedication threshold groups.
RESULTS: 347 subjects were included in the analysis, of whom 279 (80%) were in the ≤4 h group. Any contrast reaction occurred in 8 of 279 patients (3%) in the ≤ 4-h group as compared with 3 of 68 (4%) in the >4-h group (odds ratio, 0.66; 95% confidence interval, (0.17-2.5); p = 0.52). Of the 11 patients with contrast reactions, 6 were mild, 5 were moderate, and none were severe.
CONCLUSION: The occurrence of contrast-related breakthrough reactions was not significantly higher among patients who received iodinated contrast following IV premedication in ≤ 4 h. There were no mortalities in either the ≤ 4-h or the >4-h groups.
METHODS: Retrospective cohort chart analysis across five EDs (January 2022-December 2024) of patients ≥21 years old with a documented iodinated contrast allergy, who received premedication before contrast-enhanced CT imaging. The primary outcome was the proportion of any contrast reaction (mild, moderate, or severe), as defined by the 2025 ACR Contrast Media Manual. Chi-square analysis was used to compare the reaction events in the 4-h premedication threshold groups.
RESULTS: 347 subjects were included in the analysis, of whom 279 (80%) were in the ≤4 h group. Any contrast reaction occurred in 8 of 279 patients (3%) in the ≤ 4-h group as compared with 3 of 68 (4%) in the >4-h group (odds ratio, 0.66; 95% confidence interval, (0.17-2.5); p = 0.52). Of the 11 patients with contrast reactions, 6 were mild, 5 were moderate, and none were severe.
CONCLUSION: The occurrence of contrast-related breakthrough reactions was not significantly higher among patients who received iodinated contrast following IV premedication in ≤ 4 h. There were no mortalities in either the ≤ 4-h or the >4-h groups.